AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22920807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative exergame
Number of subjects: 31
Study 20973739 — intervention group
Group type: EXPERIMENTAL
Intervention: Early SWL (within 48 hours of onset of colicky pain)
Number of subjects: 160
Study 20973739 — intervention group
Group type: COMPARATOR
Intervention: Delayed SWL (after 48 hours)
Number of subjects: 160
Study 17379048 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/d
Number of subjects: 65
Study 17379048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 16286521 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention (20 to 26 sessions)
Number of subjects: 123
Study 16286521 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity intervention (six sessions)
Number of subjects: 123
Study 16286521 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity condition (attended more than three-quarters of the sessions)
Number of subjects: 123
Study 16286521 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity and moderate-intensity interventions
Number of subjects: 123
Study 11310134 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive dental program (PDP)
Number of subjects: 180
Study 11310134 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-participating children)
Number of subjects: 180
Study 9248117 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole
Number of subjects: 60
Study 9248117 — intervention group
Group type: COMPARATOR
Intervention: 20 mg omeprazole
Number of subjects: 60
Study 8136642 — intervention group
Group type: EXPERIMENTAL
Intervention: Xianbai Buyang Huanwu Decoction (XBH)
Number of subjects: 80
Study 8136642 — intervention group
Group type: COMPARATOR
Intervention: compound hypotensor tablets and gamma‐evening primrose‐E oil capsules
Number of subjects: 80
Study 2961085 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 54
Study 2961085 — intervention group
Group type: COMPARATOR
Intervention: Spinal mobilization without rotational forces
Number of subjects: 54
Study 30931825 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training group (perceptual‐cognitive simulation training with high physiological load)
Number of subjects: 13
Study 30931825 — intervention group
Group type: COMPARATOR
Intervention: Independent training group (perceptual‐cognitive simulation training and physiological load intervention completed independently)
Number of subjects: 13
Study 30931825 — intervention group
Group type: EXPERIMENTAL
Intervention: High physiological load
Number of subjects: 13
Study 27329522 — intervention group
Group type: EXPERIMENTAL
Intervention: Total volume
Number of subjects: 117
Study 27329522 — intervention group
Group type: EXPERIMENTAL
Intervention: CE volume
Number of subjects: 117
Study 27329522 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical rim width
Number of subjects: 117
Study 27329522 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric heterogeneity
Number of subjects: 117
Study 27329522 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted predictors of OS (spherical rim width)
Number of subjects: 117
Study 27329522 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted predictors of OS (geometric heterogeneity)
Number of subjects: 117
Study 25440579 — intervention group
Group type: EXPERIMENTAL
Intervention: cTBS of visual area hMT+
Number of subjects: 8
Study 25440579 — intervention group
Group type: COMPARATOR
Intervention: cTBS of areas V1/V2
Number of subjects: 8
Study 25440579 — intervention group
Group type: COMPARATOR
Intervention: cTBS of the vertex (control)
Number of subjects: 8
Study 23803341 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate sodium
Number of subjects: 19
Study 23803341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 21486181 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase I periodontal therapy
Number of subjects: 72
Study 21486181 — intervention group
Group type: COMPARATOR
Intervention: Control group (AMI without chronic periodontitis)
Number of subjects: 72
Study 19808745 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia / analgesia (EA) group
Number of subjects: 60
Study 19808745 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with i/v opiate analgesia (GA) group
Number of subjects: 60
Study 16917115 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (0.4 mg/kg)
Number of subjects: 30
Study 16917115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14687247 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-protein diet supplemented with essential amino acids and ketoacids (Ketodiet)
Number of subjects: 28
Study 14687247 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD)
Number of subjects: 28
Study 14687247 — intervention group
Group type: COMPARATOR
Intervention: Healthy sex- and age-matched subjects (Control)
Number of subjects: 28
Study 11397619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 gram IV
Number of subjects: 0
Study 11397619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 250 mg IM
Number of subjects: 0
Study 11397619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg orally
Number of subjects: 0
Study 9428435 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWL+push back
Number of subjects: 30
Study 9428435 — intervention group
Group type: COMPARATOR
Intervention: ESWL in situ
Number of subjects: 30
Study 8098446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian ablation
Number of subjects: 332
Study 8098446 — intervention group
Group type: COMPARATOR
Intervention: CMF chemotherapy
Number of subjects: 332
Study 8098446 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 7.5 mg daily for 5 years
Number of subjects: 332
Study 8098446 — intervention group
Group type: COMPARATOR
Intervention: No prednisolone
Number of subjects: 332
Study 2892255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg at bedtime
Number of subjects: 0
Study 2892255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg b.i.d.
Number of subjects: 0
Study 2892255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 25 mg b.i.d.
Number of subjects: 0
Study 2892255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29708031 — intervention group
Group type: EXPERIMENTAL
Intervention: RemoweLL device (Group B)
Number of subjects: 44
Study 29708031 — intervention group
Group type: COMPARATOR
Intervention: Standard device (Group A)
Number of subjects: 44
Study 27150898 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA
Number of subjects: 30
Study 27150898 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetal (AC)
Number of subjects: 30
Study 27150898 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyamide (PA)
Number of subjects: 30
Study 27150898 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study 25260983 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium suppository
Number of subjects: 180
Study 25260983 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen suppository
Number of subjects: 180
Study 25260983 — intervention group
Group type: COMPARATOR
Intervention: Control group (no analgesic)
Number of subjects: 180
Study 23475442 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC videolaryngoscope with stylet
Number of subjects: 120
Study 23475442 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC videolaryngoscope without stylet
Number of subjects: 120
Study 23475442 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope with stylet
Number of subjects: 120
Study 23475442 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope without stylet
Number of subjects: 120
Study 23475442 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC videolaryngoscope
Number of subjects: 120
Study 21797795 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of angiotensin II receptor antagonist (ARB) and controlled-release nifedipine (20-40 mg)
Number of subjects: 18
Study 21797795 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose combination of losartan 50 mg and hydrochlorothiazide 12.5 mg
Number of subjects: 18
Study 18772269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 335
Study 18772269 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 335
Study 18772269 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dietary and exercise intervention
Number of subjects: 335
Study 18772269 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 335
Study 18772269 — intervention group
Group type: COMPARATOR
Intervention: Control group (dietary only)
Number of subjects: 335
Study 18772269 — intervention group
Group type: COMPARATOR
Intervention: Control group (exercise only)
Number of subjects: 335
Study 18772269 — intervention group
Group type: COMPARATOR
Intervention: Control group (dietary and exercise)
Number of subjects: 335
Study 18772269 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased exercise
Number of subjects: 335
Study 18772269 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fiber intake
Number of subjects: 335
Study 16999056 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetically enhanced amoxicillin/clavulanate (2,000/125 mg) twice daily
Number of subjects: 2482
Study 12580651 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatorlode (CHO)
Number of subjects: 7
Study 12580651 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 7
Study 10691221 — intervention group
Group type: EXPERIMENTAL
Intervention: BFCN (bupivacaine 2.5 mg, fentanyl 25 microg, clonidine 30 microg, neostigmine 10 microg)
Number of subjects: 45
Study 10691221 — intervention group
Group type: COMPARATOR
Intervention: BF (bupivacaine 2.5 mg, fentanyl 25 microg)
Number of subjects: 45
Study 10691221 — intervention group
Group type: COMPARATOR
Intervention: BFC (bupivacaine 2.5 mg, fentanyl 25 microg, clonidine 30 microg)
Number of subjects: 45
Study 7855199 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.3% and 0.6%)
Number of subjects: 9
Study 7855199 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (20% and 40%)
Number of subjects: 9
Study 7855199 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.0%)
Number of subjects: 9
Study 7855199 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide (0%)
Number of subjects: 9
Study 2595800 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 138
Study 2595800 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose solution
Number of subjects: 138
Study 1092729 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg naproxen
Number of subjects: 36
Study 1092729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31642953 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 63
Study 31642953 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 63
Study 31502297 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized chance of longer survival measure
Number of subjects: 0
Study 31502297 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazard ratio
Number of subjects: 0
Study 31502297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric estimation and inference procedures
Number of subjects: 0
Study 28285751 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.06 mg/kg daily)
Number of subjects: 84
Study 28285751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 25436620 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 sets of 8‐10 repetitions at 70% 1RM
Number of subjects: 11
Study 25436620 — intervention group
Group type: COMPARATOR
Intervention: 1 set of 8‐10 repetitions at 70% 1RM
Number of subjects: 11
Study 25436620 — intervention group
Group type: COMPARATOR
Intervention: 3 sets of 8‐10 repetitions at 70% 1RM
Number of subjects: 11
Study 24872136 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Number of subjects: 170
Study 24872136 — intervention group
Group type: COMPARATOR
Intervention: E/C/F/TDF
Number of subjects: 170
Study 21748366 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) only at 5 or 10 g/day
Number of subjects: 0
Study 21748366 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) + recombinant human growth hormone (rhGH) at 0, 3.0 or 5.0 μg/kg/day
Number of subjects: 0
Study 21748366 — intervention group
Group type: COMPARATOR
Intervention: Both groups combined
Number of subjects: 0
Study 21748366 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire cohort, T only, and T + rhGH groups
Number of subjects: 0
Study 18978489 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (24 mg/d)
Number of subjects: 86
Study 18978489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 17900228 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.15%
Number of subjects: 19
Study 17900228 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 19
Study 15057253 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 86
Study 15057253 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 86
Study 15057253 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 86
Study 11575407 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (4‐6 mg kg(‐1) h(‐1))
Number of subjects: 40
Study 11575407 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1 MAC)
Number of subjects: 40
Study 9613540 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive intercostal blocks (10-20 mL 0.5% bupivacaine, 2-4 times per day for 3-6 days; n = 17)
Number of subjects: 126
Study 9613540 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural injections via a catheter (20 mL 0.25%, 4-6 times per day for 3-6 days; n = 25 for right, n = 12 for left)
Number of subjects: 126
Study 9613540 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mL 0.125% bupivacaine (n = 18)
Number of subjects: 126
Study 9613540 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mL 0.25% bupivacaine (n = 20)
Number of subjects: 126
Study 9613540 — intervention group
Group type: COMPARATOR
Intervention: Control (systemic analgesia only: patient‐controlled analgesia with opioids; n = 26)
Number of subjects: 126
Study 9613540 — intervention group
Group type: COMPARATOR
Intervention: 50 mL saline (Control; n = 21)
Number of subjects: 126
Study 7627864 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal drainage during saline infusion
Number of subjects: 3
Study 7627864 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal drainage during mannitol infusion
Number of subjects: 3
Study 7627864 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-drainage during saline infusion
Number of subjects: 3
Study 7627864 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-drainage during mannitol infusion
Number of subjects: 3
Study 7627864 — intervention group
Group type: COMPARATOR
Intervention: Control group during first 4-h session
Number of subjects: 3
Study 7627864 — intervention group
Group type: COMPARATOR
Intervention: Control group during second session
Number of subjects: 3
Study 2035049 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper/pencil format
Number of subjects: 100
Study 2035049 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer format
Number of subjects: 100
Study 2035049 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude estimation method
Number of subjects: 100
Study 2035049 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear analogue scaling method
Number of subjects: 100
Study 2035049 — intervention group
Group type: EXPERIMENTAL
Intervention: Context effects
Number of subjects: 100
Study 2035049 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewers
Number of subjects: 100
Study 6111295 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine fumarate (antihistamine H1-antagonist)
Number of subjects: 0
Study 6111295 — intervention group
Group type: COMPARATOR
Intervention: Control (no clemastine treatment)
Number of subjects: 0
Study 30720587 — intervention group
Group type: EXPERIMENTAL
Intervention: Early integrated ART during TB treatment
Number of subjects: 642
Study 30720587 — intervention group
Group type: EXPERIMENTAL
Intervention: Early integrated ART during TB treatment (adjusted for noncompliance)
Number of subjects: 642
Study 30720587 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effect of ART exposure (time-varying IV analysis)
Number of subjects: 642
Study 29035677 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone intervention using the Noom app for weight loss (15 weeks)
Number of subjects: 104
Study 29035677 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone intervention using the Noom app for weight loss (52 weeks follow-up)
Number of subjects: 104
Study 25805628 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (C)
Number of subjects: 12
Study 25805628 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (B)
Number of subjects: 12
Study 24220376 — intervention group
Group type: EXPERIMENTAL
Intervention: Merocel nasal tampon within glove finger moistened with tetracaine 0.25% solution, removed after 24 hours
Number of subjects: 80
Study 24220376 — intervention group
Group type: EXPERIMENTAL
Intervention: Merocel nasal tampon within glove finger moistened with tetracaine 0.25% solution, removed after 48 hours
Number of subjects: 80
Study 24220376 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 24220376 — intervention group
Group type: EXPERIMENTAL
Intervention: Merocel nasal tampon removed after 24 hours
Number of subjects: 80
Study 21883127 — intervention group
Group type: EXPERIMENTAL
Intervention: Early group (100 patients)
Number of subjects: 200
Study 21883127 — intervention group
Group type: EXPERIMENTAL
Intervention: Late group (100 patients)
Number of subjects: 200
Study 21883127 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 patients)
Number of subjects: 200
Study 19793371 — intervention group
Group type: EXPERIMENTAL
Intervention: Free right atrial wall (A)
Number of subjects: 142
Study 19793371 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial appendage (B)
Number of subjects: 142
Study 19793371 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary sinus ostium (C)
Number of subjects: 142
Study 19793371 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual site right atrial pacing (CS‐Os + RAA) (D)
Number of subjects: 142
Study 17767166 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2140023
Number of subjects: 0
Study 17767166 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0
Study 17767166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15282385 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (BUD) 200 micro g + formoterol (FM) 6 micro g (two puffs twice daily)
Number of subjects: 20
Study 15282385 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 250 micro g + salmeterol (SM) 50 micro g (one puff twice daily)
Number of subjects: 20
Study 11147897 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (34 degrees C) for 48 hours, followed by rewarming at 1 degrees C per day for 3 days
Number of subjects: 91
Study 11147897 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (37 degrees C) for 5 days
Number of subjects: 91
Study 9769262 — intervention group
Group type: EXPERIMENTAL
Intervention: RTCS-directed respiratory care
Number of subjects: 145
Study 9769262 — intervention group
Group type: COMPARATOR
Intervention: Physician-directed respiratory care
Number of subjects: 145
Study 7987868 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 54
Study 7987868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 2847687 — intervention group
Group type: EXPERIMENTAL
Intervention: Live, attenuated cytomegalovirus (CMV) vaccination (Towne strain)
Number of subjects: 172
Study 2847687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 29879369 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zealand Secretion Scale (NZSS) scored by experts
Number of subjects: 28
Study 29879369 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zealand Secretion Scale (NZSS) scored by untrained raters
Number of subjects: 28
Study 29178725 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthwash with anti-discoloration system (CHX+ADS)
Number of subjects: 22
Study 29178725 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine mouthwash without anti-discoloration system (CHX)
Number of subjects: 22
Study 25777831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (IV tPA) + Solitaire revascularization device
Number of subjects: 833
Study 25777831 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tissue plasminogen activator (IV tPA) alone
Number of subjects: 833
Study 23740224 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 404
Study 23740224 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 404
Study 23740224 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endpoint (Dabigatran + Warfarin)
Number of subjects: 404
Study 21359209 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-face recognition
Number of subjects: 20
Study 21359209 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived social status of the boss
Number of subjects: 20
Study 21359209 — intervention group
Group type: EXPERIMENTAL
Intervention: Boss's face presented with a labmate's face
Number of subjects: 20
Study 21359209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural differences in self-processing
Number of subjects: 20
Study 18317244 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0
Study 18317244 — intervention group
Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 0